Orexo AB
Orexo AB is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Orexo AB.
Orexo AB is a company.
Key people at Orexo AB.
Orexo AB is a Swedish commercial-stage pharmaceutical company specializing in improved pharmaceuticals based on proprietary drug delivery technologies, such as the sublingual platform and AmorphOX® powder-based technology.[1][2][3][5] It operates through segments including US Pharma (sales of pharmaceuticals like ZUBSOLV for opioid use disorder), Digital Therapeutics (DTx), and HQ & Pipelines (out-licensed products and R&D), serving patients with opioid addiction, cancer breakthrough pain, and emerging areas like overdose rescue and endometriosis.[1][2][3] The company addresses unmet medical needs by enhancing drug efficacy, bioavailability, and patient compliance, with a strong US presence combating the opioid crisis and a pipeline including OX124 (naloxone for opioid overdose), OX125 (nalmefene rescue), OX640 (epinephrine for allergies), and OXMPI (endometriosis).[3][4]
Founded in 1994 and listed on the Stockholm Stock Exchange since 2005, Orexo has grown from early diagnostics to a global player with products commercialized in the US and partnerships worldwide, emphasizing empathy-driven innovation for patients and healthcare professionals.[1][2][3]
Orexo AB was founded on November 18, 1994, by Thomas Lundqvist in Uppsala, Sweden, initially focusing on pharmaceutical research and development.[1][2] Its first product, Diabact UBT—a breath test for diagnosing Helicobacter pylori, the cause of stomach ulcers—launched in 2000, marking early traction in diagnostics.[3] In 2003, the company rebranded to Orexo, and by 2005, it listed on the Stockholm Stock Exchange.[3]
A pivotal shift occurred in 2008 with the finalization of Abstral, the first product from its world-leading sublingual drug delivery platform for breakthrough cancer pain.[3] In 2010, Novo A/S became the largest shareholder via a rights issue, prompting a strategic pivot toward US commercialization.[3] This led to establishing a US subsidiary in 2013 and launching ZUBSOLV, a sublingual buprenorphine/naloxone treatment for opioid use disorder.[3] Key milestones include a 2018 patent victory against Teva/Actavis, securing ZUBSOLV protection until 2032.[3]
Orexo rides the wave of advanced drug formulation technologies amid rising demand for effective opioid use disorder (OUD) treatments, fueled by the ongoing US opioid crisis and global needs for overdose reversal agents.[3][4] Timing aligns with post-pandemic emphasis on accessible, innovative pharma solutions, where proprietary platforms like AmorphOX® enable high-dose delivery without needles, addressing limitations in current epinephrine and naloxone products.[4] Market forces favoring Orexo include patent protections (e.g., ZUBSOLV to 2032), US market expansion, and partnerships broadening into endometriosis and allergies.[3][4] It influences the ecosystem by pioneering sublingual and digital therapeutics, advocating for policy changes, and expanding proprietary tech to new areas, supporting a shift toward patient-friendly, high-efficacy drugs.[2][3][4]
Orexo is poised for growth through pipeline approvals like OX124 for high-dose opioid rescue, leveraging AmorphOX® to enter allergies and beyond, while strengthening US OUD leadership.[3][4] Trends like escalating overdose rates and demand for needle-free delivery will propel its technologies, with potential for more partnerships and global expansion.[4] Its influence may evolve from niche innovator to broader pharma player, consistently delivering on its 30-year vision of life-improving treatments rooted in Uppsala.[2][5]
Key people at Orexo AB.
